Enhertu (Trastuzumab deruxtecan Vials) 100mg

Enhertu (trastuzumab deruxtecan) is a targeted therapy used in cancer treatment. This 100mg vial formulation is stored at 2-8°C and requires careful handling. Enhertu is prescribed under medical supervision for specific oncology indications.

Strength

100mg

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Daiichi Sankyo-Astra Zeneca

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Enhertu is used to treat certain types of cancer, including HER2-positive breast cancer and other HER2-expressing tumors. It is designed for patients who have received prior therapies. This medication targets cancer cells with HER2 proteins, helping to slow disease progression. Enhertu is typically administered in clinical settings by healthcare professionals.

Side Effects

Patients may experience effects such as nausea, fatigue, or decreased appetite during treatment. Some individuals report hair thinning or changes in blood cell counts. These effects vary by person and are monitored throughout therapy. Regular check-ups help assess how the body responds to Enhertu.

Precautions & Warnings

Enhertu requires storage at 2-8°C and should be protected from light. It must be handled by trained professionals to minimize exposure risks. Patients should report any signs of infection, breathing difficulties, or unusual symptoms immediately. Pregnant individuals or those planning pregnancy should avoid handling this medication.

Avoid Interactions

Enhertu may interact with other medications, including strong CYP3A4 inhibitors or inducers. Blood thinners and drugs affecting heart rhythm should be used with caution. Patients should inform their healthcare provider about all current medications before starting Enhertu. Alcohol consumption may exacerbate certain side effects.

References

Frequently Asked Questions

Enhertu is used to treat certain HER2-positive cancers, including breast cancer, under medical supervision.

Enhertu is given as an intravenous infusion by healthcare professionals in a clinical setting.

Common effects include nausea, fatigue, and changes in blood cell counts, which are monitored during treatment.

No, Enhertu must be stored at 2-8°C and protected from light until use.

Enhertu may interact with CYP3A4 inhibitors or inducers; consult your healthcare provider for details.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.